| Dr Brittany Lee Goss, DO | |
|
3273 Claremont Way, 209, Napa, CA 94558-3306 | |
| (707) 252-1035 | |
| (707) 252-1062 |
| Full Name | Dr Brittany Lee Goss |
|---|---|
| Gender | Female |
| Speciality | Rheumatology |
| Experience | 19 Years |
| Location | 3273 Claremont Way, Napa, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093911356 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | OS 9964 (Florida) | Secondary |
| 207RR0500X | Internal Medicine - Rheumatology | 20A11329 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Queen Of The Valley Medical Center | Napa, CA | Hospital |
| Adventist Health St Helena | Saint helena, CA | Hospital |
| Sonoma Valley Hospital | Sonoma, CA | Hospital |
| Adventist Health Clearlake | Clearlake, CA | Hospital |
| Sutter Medical Center, Sacramento | Sacramento, CA | Hospital |
| Entity Name | Brittany L Goss, Do, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649589383 PECOS PAC ID: 0143417204 Enrollment ID: O20101216000874 |
News Archive
4SC AG, a drug discovery and development company, today announced that the first patient has been dosed in the Phase I/II SHORE study with the oral pan-histone deacetylase (HDAC) inhibitor resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer.
Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.
Very-low-birthweight preterm infants with thrombocytopenia treated with cyclooxygenase inhibitors are at an increased risk for intracerebral hemorrhage, particularly if they have decreased platelet levels, research shows.
Roll Call: Billy Tauzin, the former Louisiana lawmaker, will leave his job as the president of the Pharmaceutical Research and Manufacturers of America next Wednesday, and part ways - for the first time in 18 years - with his trusty communications director, Ken Johnson. As Roll Call puts it, "The sun is setting on a K Street bromance." Tauzin is likely to start a lobbying firm with his son Tom or practice law in Texas, while Johnson will pursue other work. The two were said to be "attached at the hip" (Murray, 6/23).
With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL) - the most common type of childhood cancer - is often hailed as one of the "success stories" of modern cancer treatment. But up to 20 percent of patients with a high risk of relapse are not cured. That could change with the results from a clinical trial co-led by investigators from NYU Langone Medical Center, which shows giving high doses of a commonly-used chemotherapy drug increases the survival rate for these patients.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brittany Lee Goss, DO 3273 Claremont Way, 209, Napa, CA 94558-3306 Ph: (707) 252-1035 | Dr Brittany Lee Goss, DO 3273 Claremont Way, 209, Napa, CA 94558-3306 Ph: (707) 252-1035 |
News Archive
4SC AG, a drug discovery and development company, today announced that the first patient has been dosed in the Phase I/II SHORE study with the oral pan-histone deacetylase (HDAC) inhibitor resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer.
Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.
Very-low-birthweight preterm infants with thrombocytopenia treated with cyclooxygenase inhibitors are at an increased risk for intracerebral hemorrhage, particularly if they have decreased platelet levels, research shows.
Roll Call: Billy Tauzin, the former Louisiana lawmaker, will leave his job as the president of the Pharmaceutical Research and Manufacturers of America next Wednesday, and part ways - for the first time in 18 years - with his trusty communications director, Ken Johnson. As Roll Call puts it, "The sun is setting on a K Street bromance." Tauzin is likely to start a lobbying firm with his son Tom or practice law in Texas, while Johnson will pursue other work. The two were said to be "attached at the hip" (Murray, 6/23).
With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL) - the most common type of childhood cancer - is often hailed as one of the "success stories" of modern cancer treatment. But up to 20 percent of patients with a high risk of relapse are not cured. That could change with the results from a clinical trial co-led by investigators from NYU Langone Medical Center, which shows giving high doses of a commonly-used chemotherapy drug increases the survival rate for these patients.
› Verified 4 days ago
Marvin D. Sakakihara, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 3285 Claremont Way, Napa, CA 94558 Phone: 707-258-2500 | |
Ali Akhavan, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2100 Napa Vallejo Hwy, Napa, CA 94558 Phone: 707-253-5000 Fax: 805-466-6011 | |
Dr. Thomas T. Paukert, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3443 Villa Ln, Suite 6, Napa, CA 94558 Phone: 707-252-8407 Fax: 707-252-8335 | |
Mr. Daryl Russell Dizmang, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 935 Trancas St, Suite 3a, Napa, CA 94558 Phone: 707-253-7861 Fax: 707-253-8106 | |
Maia Eng, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1100 Trancas St Ste 240, Napa, CA 94558 Phone: 707-253-1036 | |
Ronald E Julis, M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 3273 Claremont Way Ste 201, Napa, CA 94558 Phone: 707-252-0313 Fax: 707-252-0320 |